{"filing":{"accession_number":"0001628280-26-053849","cik":"0001267565","ticker":"COLL","company_name":"COLLEGIUM PHARMACEUTICAL, INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"coll-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/coll-20260806.htm"},"events":[{"id":25865,"run_id":23482,"accession_number":"0001628280-26-053849","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Collegium Pharmaceutical disclosed second quarter 2026 financial results on August 6, 2026, reporting quarterly net revenues of $199.9 million (up 6% year-over-year), a GAAP net loss of $15.1 million, and adjusted EBITDA of $113.8 million. The company also updated full-year 2026 financial guidance, lowering Product Revenues guidance to $825–$855 million and Adjusted EBITDA guidance to $445–$470 million.","company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26798,"accession_number":"0001628280-26-053849","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Collegium Pharmaceutical's financial results for the quarter ended June 30, 2026. The press release, furnished as Exhibit 99.1 under Item 2.02, reports quarterly net revenues of $199.9 million (up 6% YoY), GAAP net loss of ($15.1) million, and adjusted EBITDA of $113.8 million, along with updated full-year 2026 financial guidance. The disclosure includes detailed segment performance (JORNAY PM, AZSTARYS, pain portfolio) and is accompanied by a scheduled earnings conference call.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:41.512013+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26799,"accession_number":"0001628280-26-053849","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Collegium Pharmaceutical's second quarter 2026 financial results, including quarterly net revenues of $199.9 million (up 6% YoY), GAAP net loss of ($15.1) million, and adjusted EBITDA of $113.8 million. The company also updated full-year 2026 financial guidance, lowering Product Revenues guidance to $825–$855 million and Adjusted EBITDA guidance to $445–$470 million. This is a standard earnings release furnished under Item 7.01 (Regulation FD Disclosure) with the presentation attached as Exhibit 99.2.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:41.512013+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26798,"accession_number":"0001628280-26-053849","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Collegium Pharmaceutical's financial results for the quarter ended June 30, 2026. The press release, furnished as Exhibit 99.1 under Item 2.02, reports quarterly net revenues of $199.9 million (up 6% YoY), GAAP net loss of ($15.1) million, and adjusted EBITDA of $113.8 million, along with updated full-year 2026 financial guidance. The disclosure includes detailed segment performance (JORNAY PM, AZSTARYS, pain portfolio) and is accompanied by a scheduled earnings conference call.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:41.512013+00:00","company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","filing_date":"2026-08-06"},{"id":26799,"accession_number":"0001628280-26-053849","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Collegium Pharmaceutical's second quarter 2026 financial results, including quarterly net revenues of $199.9 million (up 6% YoY), GAAP net loss of ($15.1) million, and adjusted EBITDA of $113.8 million. The company also updated full-year 2026 financial guidance, lowering Product Revenues guidance to $825–$855 million and Adjusted EBITDA guidance to $445–$470 million. This is a standard earnings release furnished under Item 7.01 (Regulation FD Disclosure) with the presentation attached as Exhibit 99.2.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:41.512013+00:00","company_name":"COLLEGIUM PHARMACEUTICAL, INC","ticker":"COLL","filing_date":"2026-08-06"}]}